Nuvalent (NUVL) stock ripped higher on June 9 after GSK (GSK) announced a $10.6 billion all-cash deal to acquire the Nasdaq-listed precision oncology company.
The British pharmaceutical behemoth will commence a tender offer at $124 per share, representing a massive 40% premium on NUVL’s previous close.